Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to -$2.2 million.

  • Iradimed's Cash from Financing Activities fell 1427.45% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.1 million, marking a year-over-year increase of 2492.39%. This contributed to the annual value of -$14.3 million for FY2024, which is 497.53% down from last year.
  • Per Iradimed's latest filing, its Cash from Financing Activities stood at -$2.2 million for Q3 2025, which was down 1427.45% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Cash from Financing Activities registered a high of $54154.0 during Q3 2021, and its lowest value of -$13.3 million during Q1 2023.
  • For the 5-year period, Iradimed's Cash from Financing Activities averaged around -$2.5 million, with its median value being -$262590.0 (2023).
  • In the last 5 years, Iradimed's Cash from Financing Activities soared by 10169.97% in 2021 and then plummeted by 3453613.26% in 2022.
  • Iradimed's Cash from Financing Activities (Quarter) stood at $2157.0 in 2021, then tumbled by 9300.6% to -$198457.0 in 2022, then tumbled by 32.32% to -$262590.0 in 2023, then crashed by 820.63% to -$2.4 million in 2024, then increased by 9.32% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, -$2.3 million for Q2 2025, and -$2.3 million during Q1 2025.